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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 212, Revision 2 
(FGE.212Rev2): α,β-Unsaturated alicyclic ketones and precursors from 
chemical subgroup 2.6 of FGE.19
1
 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate the genotoxic potential of 24 flavouring substances from subgroup 2.6 of 
FGE.19 in the Flavouring Group Evaluation 212, Revision 2. The Panel concluded in FGE.212, that the 
genotoxic potential could be ruled out for d-carvone [FL-no: 07.146] together with the structurally related l-
carvone [FL-no: 07.147] as well as carveol and the carvyl derivatives [FL-no: 02.062, 09.143, 09.215 and 
09.870].  Based on available genotoxicity data and new submitted genotoxicity data from the Industry, the Panel 
concluded that the genotoxic potential could be ruled out for the 11 isophorone derivatives [FL-no: 02.083, 
02.101, 07.035, 07.098, 07.126, 07.129, 07.172, 07.175, 07.196, 07.202 and 07.255] and the two vetiveryl 
derivatives [FL-no: 02.214 and 09.821] in FGE.212Rev1 and FGE.212Rev2, respectively. For the remaining five 
substances [FL-no: 07.033, 07.094, 07.112, 07.140 and 07.219] from subgroup 2.6 there is still a genotoxicity 
concern and additional data are required. 
 
© European Food Safety Authority, 2014 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was asked to evaluate flavouring substances using the 
Procedure as referred to in the Commission Regulation (EC) No 1565/2000. 
Flavouring Group Evaluation 212 (FGE.212) concerned 23 substances. The 23 substances correspond 
to subgroup 2.6 of FGE.19. Fifteen of these substances are α,β-unsaturated alicyclic ketones [FL-no: 
07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 07.140, 07.146, 07.147, 07.172, 07.175, 
07.196, 07.202 and 07.255] and eight are precursors for such ketones [FL-no: 02.062, 02.083, 02.101, 
02.214, 09.143, 09.215, 09.821 and 09.870]. 
In the first version of this Opinion, FGE.212, the Panel expressed the following view. 
d-Carvone [FL-no: 07.146] was found genotoxic in vitro. However, d-carvone was not carcinogenic in 
mice. Therefore, the Panel concluded that this substance together with the structurally related l-
carvone [FL-no: 07.147] as well as carveol and the carvyl derivatives [FL-no: 02.062, 09.143, 09.215 
and 09.870] could be evaluated through the Procedure.  
3,5,5-Trimethylcyclohex-2-en-1-one (isophorone) [FL-no: 07.126] is genotoxic in vitro. There is also 
some evidence of carcinogenicity in male rats and equivocal evidence of carcinogenicity in male mice. 
Since a non-threshold mechanism could not be excluded based on the data currently available, the 
Panel concluded that additional data were required for isophorone in order to clarify whether 
genotoxicity occurs in vivo and whether there is a threshold for the effects observed in the target 
organs in the long-term bioassays. Therefore, an in vivo Comet assay in F344/N rats covering these 
target organs was required in addition to an in vivo bone marrow assay with oral application. Due to 
structural similarities to isophorone and lack of data that addressed concerns regarding genotoxicity, 
the remaining substances could not be evaluated through the Procedure [FL-no: 02.083, 02.101, 
02.214, 07.033, 07.035, 07.094, 07.098, 07.112, 07.129, 07.140, 07.172, 07.175, 07.196, 07.202, 
07.255 and 09.821]. Additional data on genotoxicity were requested for representative substances of 
this subgroup, according to the opinion of the Panel on Genotoxicity Test Strategy for Substances 
Belonging to Subgroups of FGE.19. 
In FGE.212Rev1, new data on genotoxicity submitted by Industry on the representative substance 
3,5,5-Trimethylcyclohex-2-en-1-one [FL-no: 07.126] were evaluated. Based on these data, the Panel 
could rule out the genotoxicity concern for isophorone and the substances structurally related to 
isophorone [FL-no: 02.083, 02.101, 07.035, 07.098, 07.129, 07.172, 07.175, 07.196, 07.202 and 
07.255]. On the other hand, the Panel could not agree with the Industry argument that isophorone 
could be representative for not only the six-carbon ring substances in subgroup 2.6 but also the five-
carbon ring substances [FL-no: 07.033, 07.094, 07.112, and 07.140 ]. For these substances additional 
data were still requested as well as for the seven-carbon ring substances [FL-no: 02.214 and 09.821]. 
The present revision of FGE.212, FGE.212Rev2, deals with the evaluation of additional genotoxicity 
data submitted by the Industry on the seven-carbon  ring substance, vetiveryl acetate [FL-no: 09.821]. 
These data are also intended to cover the corresponding alcohol moiety, vetiveryl alcohol [FL-no: 
02.214] for which there was a request for genotoxicity data in FGE.212 and FGE.212Rev1. 
Additionally, since the last revision of FGE.212, one additional five-carbon ring substance, trans-3-
methyl-2-(2-pentenyl)-2-cyclopenten-1-one [FL-no: 07.219], has been included in the FGE.  
Based on these data the Panel concluded in the present opinion that the genotoxicity concern for 
vetiveryl acetate [FL-no: 09.821] and the structurally related vetiverol [FL-no: 02.214] could be ruled 
out and that these two substances can be evaluated using the Procedure. 
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For the remaining five-carbon ring substances [FL-no: 07.033, 07.094, 07.112, 07.140 and 07.219] 
from subgroup 2.6 there is still a genotoxicity concern and additional data are required. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008
4
 of the European Parliament 
and Council of 16 December 2008 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of article 9(a) of this Regulation an evaluation and 
approval are required for flavouring substances. 
The Union List of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012
5
. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000
6
. 
EFSA has evaluated 23 flavouring substances, which correspond to subgroup 2.6 of FGE.19, in its 
evaluation of the flavouring group 212 (FGE.212 and FGE.212Rev1). The opinions were adopted on 
27 November 2008 and on 25 November 2010. 
EFSA concluded that a genotoxic potential of seven α,β-unsaturated alicyclic ketones and precursors 
in the present FGE.212 could not be ruled out. 
Information on one representative material, vetiveryl acetate [FL-no: 09.821], has now been submitted 
by the European Flavour Association. This information is intended to cover the re-evaluation of this 
substance and of vetiverol [FL-no: 02.214]. 
The commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substances. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on the following two flavouring substances: vetiveryl acetate [FL-no: 09.821] and 
vetiverol [FL-no: 02.214] in accordance with Commission Regulation (EC) No 1565/2000
6
. 
                                                     
4  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
5  EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting 
the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the 
Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and 
repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1-
161. 
6  Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96 of the European Parliament and of the Council. OJ L 
180, 19.7.2000, p. 8-16. 
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HISTORY OF THE EVALUATION OF FGE.19 SUBSTANCES 
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register 
being α,β-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl 
substances via hydrolysis and / or oxidation (EFSA, 2008a). 
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA, 
2008a). The Panel noted that there were limited genotoxicity data on these flavouring substances but 
that positive genotoxicity studies were identified for some substances in the group. 
The α,β-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity 
(EFSA, 2008a). In an attempt to decide which of the substances could go through the Procedure, a 
(quantitative) structure-activity relationship (Q)SAR prediction of the genotoxicity of these substances 
was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE 
Models and ISS-Local Models, (Gry et al., 2007)). 
The Panel noted that for most of these models internal and external validation has been performed, but 
considered that the outcome of these validations was not always extensive enough to appreciate the 
validity of the predictions of these models for these alpha, beta- unsaturated carbonyls. Therefore, the 
Panel considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and 
decided not to take substances through the procedure based on negative (Q)SAR predictions only. 
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva, 
2007a; Benigni and Netzeva, 2007b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; 
Nikolov et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as 
well as data on carcinogenicity for several substances. Based on these data the Panel decided that 15 
subgroups (1.1.1, 1.2.1, 1.2.2, 1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 
2008a) could not be evaluated through the Procedure due to concern with respect to genotoxicity. 
Corresponding to these subgroups, 15 Flavouring Group Evaluations (FGEs) were established: 
FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219, 221, 222, 223, 224 and 225. 
For 11 subgroups the Panel decided, based on the available genotoxicity data and (Q)SAR predictions, 
that a further scrutiny of the data should take place before requesting additional data from the 
Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203, 210, 212, 
213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218 it was concluded that a 
genotoxic potential could be ruled out and accordingly these substances will be evaluated using the 
Procedure. For all or some of the substances in the remaining FGEs, FGE.201, 203, 210, 212, 213, 
216, 217 and 220, the genotoxic potential could not be ruled out. 
To ease the data retrieval of the large number of structurally related α,β-unsaturated substances in the 
different subgroups for which additional data are requested, EFSA worked out a list of representative 
substances for each subgroup (EFSA, 2008c). Likewise an EFSA genotoxicity expert group has 
worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 2008b). 
The Flavouring Industry has been requested to submit additional genotoxicity data according to the list 
of representative substances and test strategy for each subgroup. 
The Flavouring industry has now submitted additional data and the present FGE concerns the 
evaluation of these data requested on genotoxicity. 
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ASSESSMENT 
1. History of the Evaluation of the Substances in the Present FGE 
Flavouring Group Evaluation 212 (FGE.212) concerned 23 substances. The 23 substances, 
corresponding to subgroup 2.6 of FGE.19. Fifteen of these substances are α,β-unsaturated alicyclic 
ketones [FL-no: 07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 07.140, 7.146, 07.147, 
07.172, 07.175, 07.196, 07.202 and 07.255] and eight are precursors for such ketones [FL-no: 02.062, 
02.083, 02.101, 02.214, 09.143, 09.215, 09.821 and 09.870]. 
In FGE.212 the Panel concluded that based on available data the concern for genotoxicity could be 
ruled out for d-carvone [FL-no: 07.146], l-carvone [FL-no: 07.147], as well as carveol and carvyl 
derivatives in subgroup 2.6 [FL-no: 02.062, 09.143, 09.215 and 09.870]. Therefore these substances 
could be evaluated through the Procedure. For isophorone [FL-no: 07.126] and the structurally-related 
substances [FL-no: 02.083, 02.101, 02.214, 07.033, 07.035, 07.094, 07.098, 07.112, 07.129, 07.140, 
07.172, 07.175, 07.196, 07.202, 07.255 and 09.821] additional genotoxicity data were requested for 
representative substances according to the Test Strategy (EFSA, 2008b). In the EFSA Opinion “List of 
α,β-unsaturated aldehydes and ketones representative of FGE.19 substances for genotoxicity testing” 
(EFSA, 2008c), representative flavouring substances have been selected for subgroup 2.6 (Table 1), 
corresponding to FGE.212, for which additional data on genotoxicity were requested. 
In FGE.212Rev1, new data on genotoxicity were submitted by Industry on the representative 
substance 3,5,5-Trimethylcyclohex-2-en-1-one [FL-no: 07.126]. Based on these data the Panel 
concluded that the concern for genotoxicity could be ruled out for [FL-no: 07.126] and for the 10 six-
carbon ring substances of subgroup 2.6 [FL-no: 02.083, 02.101, 07.035, 07.098, 07.129, 07.172, 
07.175, 07.196, 07.202 and 07.255]. For the six remaining substances in FGE.212 [FL-no: 02.214, 
07.033, 07.094, 07.112, 07.140 and 09.821] additional genotoxicity data were still requested. 
 
The present revision of FGE.212, revision 2 (FGE.212Rev2) concerns the evaluation of additional 
genotoxicity data submitted by the Industry (IOFI, 2012) for one of the seven-carbon ring substances 
of subgroup 2.6, namely vetiveryl acetate [FL-no: 09.821] which is structurally related to vetiverol 
[FL-no: 02.214]
7
. For the five-membered ring substances of subgroup 2.6 [FL-no: 07.033, 07.094, 
07.112 and 07.140] additional genotoxicity data are requested. Additionally, since the last revision of 
FGE.212 one additional five-carbon ring substance, trans-3-methyl-2-(2-pentenyl)-2-cyclopenten-1-
one [FL-no: 07.219], has been included in the FGE. 
                                                     
7
  Vetiverol [FL-no: 02.214], representing the 7-carbon ring substances, are not in common use in the flavour industry. The 
acetyl ester of [FL-no: 02.214], vetiveryl acetate [FL-no: 09.821] is in more common use, and on that basis was available 
for testing. Therefore, this report presents data for the vetiveryl acetate (REF:7521). 
FGE Adopted by 
EFSA 
Link No. of 
Substances 
FGE.212 27 November 
2008 
http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1211902780085.htm 
23 
FGE.212Rev1 November 2010 http://www.efsa.europa.eu/en/efsajournal/pub/1923.htm 23 
FGE.212Rev2 January 2014  24 
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Table 1:  Representative substances for subgroup 2.6 of FGE.19 (EFSA, 2008c) 
FL-no  
JECFA-no  
Subgroup  EU Register name  Structural formula  Comments  
02.214 
1866 
2.6  Vetiverol 
 
HO
 
Representative: 2,6-
Dimethyl-9-(1-
methylethylidene)- 
bicyclo[5.3.0]dec-2-en-4-
one (not in register) or its 
precursor [02.214]. 
07.112 
1105 
2.6 3-Methyl-2-cyclopenten-1-one O
 
 
07.126 
1112 
2.6 3,5,5-Trimethylcyclohex-2-en-1-
one (isophorone) 
O
 
  
 
Sections 2, 3 and 4 report the same information that was presented in FGE.212 and FGE.212Rev1. 
Section 5 describes additional data submitted by the Industry in response to the data requested in 
FGE.212Rev1. 
2. Presentation of the Substances in FGE.212Rev2 
2.1. Description 
The present Flavouring Group Evaluation 212 Revision 2 (FGE.212Rev2) concerns 24 substances, 
which are presented in Table 2. The 24 substances correspond to subgroup 2.6 of FGE.19 (EFSA, 
2008a). Sixteen of these substances are α,β-unsaturated alicyclic ketones (α,β-unsaturation in the side 
chain) [FL-no: 07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 07.140, 7.146, 07.147, 07.172, 
07.175, 07.196, 07.202, 07.219 and 07.255] and eight are precursors for such ketones [FL-no: 02.062, 
02.083, 02.101, 02.214, 09.143, 09.215, 09.821 and 09.870].  
Twenty-one of the substances have previously been evaluated by the JECFA at their 51
st
, 59
th
 and 69
th
 
meetings (JECFA, 1999; JECFA, 2003; JECFA, 2009a). A summary of their evaluation status by the 
JECFA is given in Table 3. 
As the α,β-unsaturated ketone structure is considered to be a structural alert for genotoxicity (EFSA, 
2008a) the available data on genotoxic or carcinogenic activity for the 16 ketones in FGE.212 [FL-no: 
07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 07.140, 7.146, 07.147, 07.172, 07.175, 
07.196, 07.202, 07.219 and 07.255] and one non-Register ketone [2,6-dimethyl-9-(1-
methylethylidene)-bicyclo[5.3.0]dec-2-en-4-one] corresponding to the 24 substances in FGE.212, will 
be considered in this FGE. 
The Panel also noted that for one substance [FL-no: 07.033], the CAS No, name and chemical 
structure were not consistent (Table 2). Therefore a clarification is needed. 
The Panel has also taken into consideration the outcome of the predictions from five selected (Q)SAR 
models (Benigni and Netzeva, 2007a; Gry et al., 2007; Nikolov et al., 2007) on 15 ketones [FL-no: 
07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 07.140, 7.146, 07.147, 07.172, 07.175, 
Flavouring Group Evaluation 212, Revision 2  
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07.196, 07.202 and 07.255] and one non-Register ketone [2,6-dimethyl-9-(1-methylethylidene)-
bicyclo[5.3.0]dec-2-en-4-one] in the original version of FGE.212. These 15 ketones and the one non-
Register ketone as well as their (Q)SAR predictions are shown in Table 4. 
3. Toxicity8 
3.1. (Q)SAR Predictions 
In Table 4 the outcomes of the (Q)SAR predictions for possible genotoxic activity in five in vitro 
(Q)SAR models (ISS Local Model-Ames test, DTU-NFI MultiCASE-Ames test, Chromosomal 
aberration test in Chinese hamster ovary cells (CHO), Chromosomal aberration test in Chinese 
hamster lung cells (CHL) and Mouse lymphoma test) are presented. 
Positive predictions have been obtained for six substances with the MultiCASE Mouse lymphoma 
model and for one of these substances also with the MultiCASE model on chromosomal aberrations. 
For the other substances, the predictions of the MultiCASE models were negative, equivocal or the 
substances were out of domain. All substances were out of domain in the ISS model. 
3.2. Carcinogenicity Studies 
Groups of 50 male and 50 female F344/N rats were administered isophorone (3,5,5-trimethylcyclohex-
2-en-1-one [FL-no: 07.126]) in corn oil by gavage at dose levels of 0 (controls),  250 or 500 mg/kg 
body weight (bw)/day, five times per week for 103 weeks. During the study the body weights of the 
high-dose male and female rats were slightly lower than those of the vehicle controls. The survival of 
high-dose male rats was significantly lower than that of the vehicle controls after week 96. Dosed 
male rats showed a variety of proliferative lesions of the kidney (tubular cell hyperplasia, 0/50, 1/50, 
4/50; tubular cell adenoma, 0/50, 0/50, 2/50; tubular cell adenocarcinoma, 0/50, 3/50, 0/50; epithelial 
hyperplasia of the renal pelvis, 0/50, 5/50, 5/50). Dosed male rats also exhibited increased 
mineralisation of the medullary collecting ducts (1/50, 31/50, 20/50) and low-dose male rats showed a 
more severe nephropathy than is commonly seen in aging F344/N rats. Carcinomas of the preputial 
gland were significantly increased (P<0.03) in high-dose male rats (0/50, 0/50, 5/50). With the 
exception of a moderate increase in nephropathy (21/50, 39/50, 32/50), female rats did not show 
chemically related increased incidences of neoplastic or non-neoplastic lesions (NTP, 1986). 
Groups of 50 male and 50 female B6C3F1 mice were administered isophorone (3,5,5-
trimethylcyclohex-2-en-1-one [FL-no: 07.126]) in corn oil by gavage at dose levels of 0 (controls), 
250 or 500 mg/kg bw/day, five times per week for 103 weeks. During the study the body weights of 
the high-dose female mice were slightly lower than those of the vehicle controls. The survival of male 
mice was low, whereas there was a significant trend toward increased survival of dosed female mice 
relative to that of the vehicle controls. In high-dose male mice, isophorone exposure was associated 
with an increased incidence of hepatocellular adenomas and carcinomas (18/48, 18/50, 29/50) and of 
mesenchymal tumors of the integumentary system (fibroma, fibrosarcoma, neurofibrosarcoma or 
sarcoma, 6/48, 7/50, 14/50). An increased incidence of lymphomas or leukemias was noted in low-
dose male mice (8/48, 18/50, 5/50). Coagulative necrosis (3/48, 10/50, 11/50) and hepatocytomegaly 
(23/48, 39/50, 37/50) were observed more frequently in the livers of dosed male mice than in vehicle 
controls. No compound-related neoplastic or non-neoplastic lesions associated with isophorone 
exposure were seen in female mice (NTP, 1986). 
The Panel concluded that isophorone increased the incidences of renal tubular cell adenomas and 
adenocarcinomas and of carcinomas of the preputial gland in male rats but not in female rats. In male 
mice, but not in females, it produced increased incidences of hepatocellular adenomas and carcinomas, 
mesenchymal tumors in the integumentary system, and malignant lymphomas. 
                                                     
8
  The data presented in Section 3 is cited from the first version of the present FGE.212. These data are the basis for the 
conclusions in FGE.212 requesting additional genotoxicity data. 
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The Panel agrees with the authors of the NTP report who concluded that “under the conditions of these 
2-year gavage studies, there was some evidence of carcinogenicity of isophorone in male F344/N rats 
as shown by the occurrence of renal tubular cell adenomas and adenocarcinomas in animals given 250 
or 500 mg/kg bw per day; carcinomas of the preputial gland were also observed at increased incidence 
in male rats given 500 mg/kg bw. There was no evidence of carcinogenicity in female F344/N rats 
given 250 or 500 mg/kg bw per day. For male B6C3F1 mice, there was equivocal evidence of 
carcinogenicity of isophorone as shown by an increased incidence of hepatocellular adenomas or 
carcinomas (combined) and of mesenchymal tumors in the integumentary system in animals given 500 
mg/kg bw per day and by an increase in malignant lymphomas in animals given 250 mg/kg bw per 
day. There was no evidence of carcinogenicity of isophorone in female B6C3F1 mice given 250 or 500 
mg/kg bw per day.” 
Groups of 50 male and 50 female B6C3F1 mice (7-week old) were administered 0, 375 or 750 mg/kg 
bw d-carvone [FL-no: 07.146] in corn oil by gavage, five days per week for 103 weeks. The mean 
body weights of dosed and control male and female mice were similar throughout most of the study. 
The survival of both the low-dose and the high-dose females were significantly greater than that of the 
controls. No differences in survival were observed between any groups of male mice. Atrophy of the 
olfactory epithelium and hyperplasia of the underlying Bowman's glands occurred together with high 
incidence in either sex in both dosed groups. This effect was found due to a local effect of d-carvone 
caused by reflux of the gavage material when the gavage needle was withdrawn. No increases in 
tumour incidences were seen in mice administered d-carvone. The incidences of male mice with 
primary neoplasms and the total numbers of primary neoplasms were significantly lower in the dosed 
groups than in the vehicle controls (NTP, 1990). 
The Panel concluded that d-carvone was not carcinogenic in mice under the study conditions. It agrees 
with the authors of the NTP report who concluded that “under the conditions of these 2-year gavage 
studies, there was no evidence of carcinogenic activity of d-carvone for male or female B6C3F1 mice 
administered 375 or 750 mg/kg, 5 days per week for 2 years.” 
Study validation and results are presented in Table 5. 
3.3. Genotoxicity Studies 
In subgroup 2.6 there are studies available for four substances: tetramethyl ethylcyclohexenone 
(mixture of isomers) [FL-no: 07.035], 3,5,5 trimethylcyclohex-2-en-1-one [FL-no: 07.126] 
(isophorone), d-carvone [FL-no: 07.146] and l-carvone [FL-no: 07.147]. 
Study validation and results are presented in Tables 6 and 7. 
3,5,5 Trimethylcyclohex-2-en-1-one [FL-no: 07.126] (isophorone) did not induce gene mutations in 
bacteria but it induced mutations in mammalian cells in a mouse lymphoma TK assay in the absence 
of metabolic activation (it was not tested in the presence of metabolic activation) (NTP, 1986). No 
mutations in the MLTK assay were observed in a study of O’Donoghue et al. (O’Donoghue et al., 
1988) at comparable concentrations. Isophorone induced chromosomal aberrations in Chinese hamster 
lung fibroblasts with and without metabolic activation (Matsuoka et al., 1996) and sister chromatid 
exchanges (SCE) in CHO cells without metabolic activation (Gulati et al., 1989). Chromosomal 
aberrations have not been observed in two other studies (Gulati et al., 1989; NTP, 1986); however, the 
validity of the results was limited because the types of aberrations were not reported. Isophorone did 
not induce unscheduled DNA synthesis (UDS) in rat hepatocytes in vitro. In vivo, isophorone was 
tested negative in a sex-linked recessive lethal mutation assay in Drosophila (Foureman et al., 1994) 
and in two micronucleus assays in mice (McKee et al., 1987; O’Donoghue et al., 1988). However, the 
Drosophila assay has only limited relevance and the micronucleus assays were of limited validity. 
Negative results were also observed with tetramethyl ethylcyclohexenone [FL-no: 07.035] in bacteria, 
in a sex-linked recessive lethal mutation assay in Drosophila (Wild et al., 1983) and in a mouse 
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micronucleus assay (Wild et al., 1983); however, there was a mixture of isomers tested and the studies 
were only of limited validity.  
d-Carvone [FL-no: 07.146] was not mutagenic in bacteria but induced SCE and chromosomal 
aberrations in CHO cells in the presence and absence of metabolic activation, respectively (NTP, 
1990). 
3.4. Conclusion on Genotoxicity and Carcinogenicity 
The Panel concluded that 3,5,5 trimethylcyclohex-2-en-1-one [FL-no: 07.126] (isophorone) is 
genotoxic in vitro while a final conclusion on the genotoxicity in vivo could not be drawn based on the 
data available. It is carcinogenic in male rats and male mice. It was also predicted to be genotoxic in 
one of the four MultiCASE models (while it was out of domain in the ISS model). 
d-Carvone [FL-no: 07.146] is genotoxic in vitro while no in vivo data were available. d-Carvone, was 
not carcinogenic in mice and was predicted to be non-genotoxic in the four MultiCASE models (while 
it was out of domain in the ISS model). No data are available on l-carvone. However, in vivo studies in 
humans show that the metabolism of ingestion-correlated amounts of d- or l-carvone occurs via a 
major oxidative pathway of the isopropylene side chain yielding diol and two carboxylic acids, 
irrespective of the stereochemical difference between the two parent isomers of carvone (Engel, 2001). 
Accordingly, the results for d-carvone can be used for l-carvone as well. 
The negative results reported from in vivo studies on the genotoxicity of tetramethyl 
ethylcyclohexenone [FL-no: 07.035] were only of limited validity. 
3.5. Conclusion 
The present Flavouring Group Evaluation 212 (FGE.212) concerns 23 substances. The 23 substances 
correspond to subgroup 2.6 of FGE.19. Fifteen of these substances are alpha,beta-unsaturated alicyclic 
ketones [FL-no: 07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 07.140, 7.146, 07.147, 
07.172, 07.175, 07.196, 07.202 and 07.255] and eight are precursors for such ketones [FL-no: 02.062, 
02.083, 02.101, 02.214, 09.143, 09.215, 09.821 and 09.870]. 
d-Carvone [FL-no: 07.146] was found genotoxic in vitro. However, d-carvone was not carcinogenic in 
mice. Therefore, the Panel concluded that this substance together with the structurally related l-
carvone [FL-no: 07.147] as well as carveol and the carvyl derivatives [FL-no: 02.062,  09.143, 09.215 
and 09.870] could be evaluated through the Procedure.  
Isophorone [FL-no: 07.126 (3,5,5-trimethylcyclohex-2-en-1-one)] is genotoxic in vitro and since there 
is some evidence of carcinogenicity in male rats and equivocal evidence of carcinogenicity in male 
mice and since a non-threshold mechanism could not be excluded based on the data currently 
available, the Panel concluded that additional data are required for isophorone in order to clarify 
whether genotoxicity occurs in vivo and whether there is a threshold for the effects observed in the 
target organs in the long-term bioassays. Therefore, an in vivo Comet assay in F344/N rats covering 
these target organs is required in addition to an in vivo bone marrow assay with oral application.  
Due to structural similarities and lack of data, the remaining substances cannot presently be evaluated 
through the Procedure [FL-no: 02.083, 02.101, 02.214, 07.033, 07.035, 07.094, 07.098, 07.112, 
07.129, 07.140, 07.172, 07.175, 07.196, 07.202, 07.255 and 09.821]. Additional data on genotoxicity 
are requested for representative substances of this subgroup according to the opinion of the Panel on 
the Genotoxicity Test Strategy for Substances Belonging to Subgroups of FGE.19 (EFSA, 2008b). 
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4. Industry Response to Data Requested in FGE.2129 
4.1. Presentation of the Additional Data 
Honma et al. (Honma et al., 1999a; Honma et al., 1999b) found that isophorone did not clearly induce 
mutations in the mouse lymphoma assay (MLA) following 3 hours treatments, but observed that it was 
mutagenic after 24 hours treatments in the absence of S9. Although only graphs are plotted, it seems 
that increases in mutation frequency (MF) that exceeded the Global Evaluation Factor (GEF) occurred 
at around 1250‐1500 μg/ml where toxicity (by relative survival) reached 70‐90 %. 
The NTP conducted a mouse bone marrow chromosomal aberration (CA) study on isophorone. 
Groups of 8 male B6C3F1 mice (larger group sizes than required by OECD) were dosed i.p. with 
isophorone at 125, 250 and 500 mg/kg bw. The standard protocol for in vivo CA is not given on the 
NTP website. However, based on Shelby and Witt (Shelby and Witt, 1995), animals should have been 
sampled at 17 hours and, if negative, also at 36 hours. The data on the NTP website are only for bone 
marrow sampled at 36 hours. It is therefore possible that a 17 hours sample was also taken, and found 
to be negative, but the data have not been posted. Fifty cells per animal were scored for CA and no 
increases in CA were seen. No measures of toxicity were recorded, but i.p. dosing should have 
guaranteed systemic exposure. The control CA frequency was normal (2.75 %) and the positive 
control (dimethylbenzanthracene) produced a significant response in CA frequency.  
A DNA binding study was conducted in which F344‐rats and B6C3F1‐mice (the strains used in the 
NTP carcinogenicity study) were exposed to isophorone (Thier et al., 1990). Animals of both sexes 
were dosed once or five times by gavage with 500 mg/kg bw of unlabelled isophorone spiked with 
[1,3,5‐14C]‐isophorone (specific activity: 52 mCi per mmol, 1.92 GBq per mmol). An additional group 
of acute dosed male rats received undiluted 
14
C‐isophorone for increased sensitivity. Rats and mice 
were maintained for 24 hours in closed metabolic cages. Twenty four hours after exposure, livers and 
kidneys (the tumour target tissues) were removed from the animals. DNA was isolated through 
hydroxyapatite chromatography and radioactivity was measured by liquid scintillation counting. No 
positive controls were included. Also no untreated controls were included, but, except for the liver 
sample of one mouse in the five times dose group, radioactivity values were within 2σ of background 
(6 dpm). Radioactivity values therefore did not indicate significant attachment of radioactivity to 
DNA. From these results it can be concluded that neither isophorone nor its metabolites bind 
covalently to DNA. 
In addition, a report by Morishita et al. (Morishita et al., 1997) submitted to EPA (EPA, 1997), is 
relevant and appears to have been previously submitted only as an abstract. This study was designed to 
investigate whether isophorone and/or α2μ‐globulin10 might be involved in the induction of preputial 
gland tumours in F‐344 rats (10/sex/dose group). A series of experiments was performed in order to 
study several parameters including: 
 binding of isophorone to DNA of kidney and preputial gland. Groups of 10 male rats were dosed 
by gavage with 500 mg/kg of [
14
C]‐isophorone (specific activity 14.65 mCi/mmol; 100 
μCi/animal). Positive control animals were dosed with 3H‐labeled methyl nitrosourea. 
 DNA adduct detection by 32P‐postlabeling in young adult male and female rats (7 per group) dosed 
by gavage with 0, 250 or 500 mg/kg isophorone for five days. 
Extraction of preputial gland and kidney DNA from rats treated with single 500 mg/kg labeled doses 
yielded no evidence of isophorone binding to DNA, whereas the positive control showed significant 
                                                     
9   The data presented in Section 4 is cited from revision 1 of FGE.212 (FGE.212Rev1). These data are the basis for the  
  conclusions in FGE.212Rev1 requesting additional genotoxicity data. 
10  Since interaction with 2 -glubulin is not of direct relevance for the evaluation of genotoxic potential, this information is  
  omitted from this study summary. 
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binding to DNA of preputial gland and kidney. These negative results with isophorone were confirmed 
in the 
32
P ‐postlabeling assays.  
In addition Industry has also asked whether the information submitted for isophorone, (cyclohexenyl 
derivative), could also be applied to evaluate the genotoxic potential of the five-carbon membered ring 
substances (i.e. cyclopentenyl derivatives) in subgroup 2.6 (letter of EFFA to EFSA, dated 14/4-2010). 
This request was supported by the argumentation that there is structural resemblance with respect to 
steric hindrance around the alpha,beta-unsaturated double bond. In addition, Industry argued that the 
-conjugation systems in these molecules is very nearly planar and that therefore the reactivity and 
genotoxic potentials of the five- and six-membered ring systems would be similar. No further data 
were provided to substantiate this argumentation.  
4.2. Discussion of the Additional Data 
Conflicting results were reported in two valid studies with the mouse lymphoma assay (MLA): one 
negative (O’Donoghue et al., 1988) and one positive (NTP, 1986) at comparable concentrations. 
Mixed results were also reported in two studies of limited validity: one negative (Honma et al., 1999a) 
and one positive (Honma et al., 1999b). Another negative result was reported in a study (McKee et al., 
1987), the validity of which cannot be evaluated. In the light of the clearly negative results in two 
valid bacterial gene mutation tests (Ames test) and in a valid Sex Linked Recessive Lethal Mutations 
test (SLRL) in Drosophila, and taking into account the lack of specificity and high sensitivity of the 
MLA, overall the results presently available are considered of questionable relevance. The Panel 
agrees that isophorone demonstrates some genotoxic activity in vitro but that the new data demonstrate 
lack of clastogenicity in vivo. In addition, the new DNA-binding data from two separate studies 
provide convincing evidence that isophorone does not induce tumours via a genotoxic mechanism. On 
the basis of these data it may be argued that there is no need to perform further in vivo genotoxicity 
studies such as the Comet assay or bone marrow micronucleus test. Thus, based on the data available 
the Panel concluded that there is no concern with respect to genotoxicity of isophorone.  
4.3. Conclusion on Additional Data 
Since based on the additional information the concern for the genotoxic potential for isophorone [FL-
no: 07.126] has been alleviated, a genotoxic potential can also be ruled out for the other structurally 
related six-carbon members of FGE.19 subgroup 2.6 related to isophorone [FL-no: 02.083, 02.101, 
07.035, 07.098,  07.129, 07.172, 07.175, 07.196, 07.202 and 07.255]. 
The Panel also concluded that isophorone can only be considered as representative for the six-carbon 
ring members of FGE.19 subgroup 2.6. The argumentation of Industry to expand this conclusion also 
to the cyclopentenyl derivatives in this subgroup [FL-no: 07.033, 07.094, 07.112 and 07.140] was 
considered too limited, given the lack of support from experimental data. Therefore, additional 
genotoxicity tests are still required for the representative substance [FL-no: 07.112] already chosen by 
the Panel. Alternatively, a more thorough explanation (physico-chemical parameters; experimental 
underpinning) of the proposed similar reactivity of six- and five-membered ring substances should be 
provided by Industry. Also for the seven-ring carbon substance [FL-no: 02.214] (also covering [FL-
no: 09.821]) additional data on genotoxicity are still required. 
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5. Industry Response to Data Requested in FGE.212Rev1 
In response to the EFSA request in FGE.212 and FGE.212Rev1 for additonal genotoxicity data for 
FGE.19 subgroup 2.6, the Flavour Industry (IOFI, 2012) has submitted in vitro genotoxicity data on: 
vetiveryl acetate [09.821]. 
5.1. In vitro Genotoxicity Studies 
Bacterial Reverse Mutation Tests 
Vetiveryl acetate containing 1 % alpha-tocopherol (a common stabiliser present in the large majority 
of  commercially available solutions of vetiveryl acetate to increase shelf-life typically for up to 18 
months) was tested in Salmonella typhimurium strains TA97, TA98, TA100, TA102 and TA1535 in 
two independent experiments in the absence and presence of metabolic activation (by liver S9-mix 
fraction from phenobarbitone/β-naphthoflavone-induced rats) (Gocke, 2000), the results are 
summarised in Table 8. The study complies with GLP and current guidelines (OECD Guideline 471, 
1997). The first experiment used the plate incorporation method and the second used the pre-
incubation method. Treatments were performed at concentrations of 0, 20, 63.2, 200, 632 and 2000 
μg/plate of stabilised vetiveryl acetate (dissolved in DMSO) with triplicate plates per test 
concentration. Some precipitation (milky appearance) was seen at the higher concentrations (> 200 
μg/plate for the plate incorporation assay and > 20 μg/plate for the pre-incubation test) and evidence of 
toxicity was observed in some strains in the pre-incubation experiments. On this basis, 2000 μg/plate 
was the highest concentration that could be practically tested. Negative results were obtained with all 
five bacterial strains in the presence and absence of S9-mix up to the maximum test concentration of 
2000 μg/plate. 
In another study, vetiveryl acetate extra (stabilisation not stated) (dissolved in DMSO) was tested in S. 
typhimurium strains TA100, TA97a, TA98, TA1535, and TA102 at concentrations ranging from 5 - 
5000 μg/plate with and without S9-mix metabolic activation (Scheerbaum, 2001). Different 
concentrations from this range were used for different strains or within the same strain in the presence 
or absence of S9-mix. Cytotoxicity, in the form of background bacteria lawn reduction, in the absence 
of S9-mix was noted at 500 μg/plate and above in strain TA100, 1600 μg/plate and above in strain 
TA1535, and 5000 μg/plate in strain TA97a. In presence of S9-mix, cytotoxicity was noted at 500 
μg/plate and above in strain TA100 and TA1535, 1600 μg/plate and above in strain TA97a and 
TA102, and 5000 μg/plate in strain TA98. No mutagenic potential was observed in any strain under 
any condition or concentration. This study design complies with published recommendations (OECD 
Guideline 471, 1997). 
A series of Ames studies were conducted with stabilised vetiveryl acetate (stabiliser identity unknown) 
that had been stored for 18 - 24 months. In one Ames study, stabilised vetiveryl acetate (stored for 18 
months) was tested for mutagenicity in S. typhimurium strains TA98, TA100, TA102, TA1535 and 
TA1537, in two separate experiments (Poth, 2003) (Table 8). Experiment 1 was conducted in all five 
tester strains at vetiveryl acetate (dissolved in DMSO) concentrations of 33, 100, 333, 1000, 2500 and 
5000 μg/plate in the absence and presence of metabolic activation system (S9-mix prepared from 
phenobarbital/β-naphthoflavone induced male Wistar rat liver). Precipitation of test material occurred 
at the highest concentration. Cytotoxicity was noted in the presence of S9-mix, at 5000 μg/plate in 
strain TA1537 and at 1000 μg/plate and above in strains TA100 and TA102. In experiment 2, using a 
modified protocol including a pre-incubation method, vetiveryl acetate was tested at the same 
concentrations up to 5000 μg/plate in the absence and presence of S9-mix in all five strains, and from 
a starting concentration of 10 μg/plate in strains TA100 and TA102 in the presence of S9-mix. 
Cytotoxicity was noted in the presence of S9-mix, at 2500 μg/plate and above in strains TA1535 and 
TA102, and at 1000 μg/plate and above in strains TA1537 and TA100. No increase in revertant 
frequencies was observed between treated and control cultures at any concentration, either in the 
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absence or in the presence of metabolic activation. This study design complies with  OECD Guideline 
471 (OECD, 1997a). 
In a second study, S. typhimurium strains TA98, TA100, TA102, TA1535 and TA1537 were incubated 
with stabilised vetiveryl acetate that had been stored for 24 months (Sokolowski, 2003a). Two 
independent experiments were performed in the absence and presence of S9-mix metabolic activation. 
The first experiment used the plate incorporation method and the second used the pre-incubation 
method. Concentrations of 0, 33, 100, 333, 1000, 2500 and 5000 μg/plate of stabilised vetiveryl 
acetate were included in each part of the study. Cytotoxicity, in the form of background bacteria lawn 
reduction, was noted in the presence of S9-mix, at 5000 μg/plate in strains TA98 (both experiments) 
and TA102 (first experiment only), at 2500 μg/plate and above in strain TA1535 (both experiments), 
and at 1000 μg/plate and above (first experiment) or 2500 μg/plate and above (second experiment) in 
strain TA1537. No increase in mutagenicity was observed in any bacterial strain, either in the presence 
or absence of S9-mix, up to the maximum test concentration of 5000 μg/plate. No precipitation of the 
test material was noted up the highest concentration tested. This study design complies with published 
recommendations (OECD Guideline 471, 1997). 
In a third study, S. typhimurium strains TA98, TA100, TA102, TA1535 and TA1537 were incubated 
with a formulation (112 extra) of stabilized vetiveryl acetate that had been stored for 24 months 
(Sokolowski, 2003b). The exact differences between the formulations of the stabilised vetiveryl 
acetate have not been determined. Two independent experiments were performed in the absence and 
presence of S9-mix metabolic activation. The first experiment used the plate incorporation method and 
the second used the pre-incubation method. The same concentrations of 0, 33, 100, 333, 1000, 2500 
and 5000 μg/plate of stabilised vetiveryl acetate were included in each experiment. Precipitation of test 
material occurred at the highest concentration. Cytotoxicity, in the form of background bacteria lawn 
reduction, in the absence of S9-mix, was noted only at the highest concentration and only in strain 
TA1535. In presence of S9-mix, cytotoxicity was noted at 5000 μg/plate in strains TA98 (second 
experiment) and TA102 (first experiment), at 2500 μg/plate and above in strain TA1535 (first 
experiment), and at 5000 μg/plate (first experiment) or 2500 μg/plate and above (second experiment) 
in strain TA1537. No increase in mutagenicity was observed in any bacterial strain, either in the 
presence or absence of S9-mix, up to the maximum test concentration of 5000 μg/plate. This study 
design complies with published recommendations (OECD Guideline 471, 1997). 
In conclusion, different formulations of vetiveryl acetate with purity and stabilisation not reported 
were tested in a number of studies with Ames assay in five strains of S. typhimurium in presence and 
absence of S9-mix. No increase of revertants was detected in any of these studies up to a concentration 
of 5000 μg/plate. 
Tests in Mammalian Cells 
A study was conducted in vitro in human lymphocytes to assess the ability of vetiveryl acetate [FL-no: 
09.821] (purity 98 % and stabilised with 1 % alpha-tocopherol) to induce structural chromosomal 
aberrations (CA), both in the absence and in the presence of metabolic activation by S9-mix, in two 
separate experiments (Morris, 2011). The study complies with GLP and OECD Guideline 473 (OECD, 
1997b). 
The initial dose levels chosen for experiment 1 and experiment 2 were based on a previous 
chromosomal aberration study conducted in Chinese Hamster Ovary (CHO) cells by Harlan 
Laboratories Ltd (Morris and Durward, 2010). While it produced negative results, the study in CHO 
cells was not considered valid due to a high percentage of cells with chromosomal aberrations in the 
vehicle controls. 
In experiment 1, duplicate lymphocytes cultures were exposed to concentrations of freshly prepared 
vetiveryl acetate of 10, 20, 30, 40, 50 and 60 μg/ml for 4 hours in the absence of S9-mix along with 
vehicle and positive (mitomycin C (MMC) 0.4 μg/ml) controls and for 4 hours in the presence of S9-
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mix (2 % final concentration) at concentrations of 40, 60, 80, 100, 110, 120, 130 and 140 μg/ml along 
with vehicle and positive (cyclophosphamide (CP) 4.5 μg/ml) controls, followed by 20 hours in 
treatment-free media. Mitosis was arrested by the addition of demecolcine (colcemid 0.1 μg/ml) two 
hours before cell harvest. The cells were processed, coded and scored for number of cells in metaphase 
and polyploidy cell frequency. Concentrations of 0, 20, 30, 40 and 45 μg/ml in the absence of S9-mix, 
and 0, 40, 60, 80 and 100 μg/ml in the presence of S9-mix were selected for quantitative analysis, 
based on toxicity seen at higher concentrations. The results indicated that vetiveryl acetate did not 
induce statistically significant increases in the frequency of cells with chromosomal aberrations at any 
concentration, either in the absence or presence of S9-mix. Also, vetiveryl acetate did not result in a 
statistically significant increase in the polyploid cell frequency at any concentration, either in the 
absence or presence of S9-mix.  
In experiment 2, duplicate cultures were exposed to concentrations of freshly prepared vetiveryl 
acetate of 10, 20, 40, 60, 80, 100, 110 and 120 μg/ml for 24 hours continuous exposure in the absence 
of S9-mix along with vehicle and positive (MMC 0.2 μg/ml) controls. Cultures were also exposed to 
vetiveryl acetate concentrations of 20, 40, 60, 80, 100, 110, 120 and 140 μg/ml for 4 hours in the 
presence of S9-mix (1 % final concentration), along with vehicle and positive (CP) controls followed 
by 20 hours in treatment-free media. Mitosis was arrested by the addition of demecolcine (colcemid 
0.1 μg/ml) two hours before cell harvest. The cells were processed, coded and scored for number of 
cells in metaphase and for polyploidy frequency. Concentrations of 0, 20, 40, 80 and 100 μg/ml 
vetiveryl acetate for 24 hour treatment and concentrations of 0, 20, 40, 60 and 80 μg/ml for 4 hours 
treatment in the presence of S9-mix were selected for quantitative analysis, based on toxicity seen at 
higher concentrations. The results indicated that vetiveryl acetate did not induce statistically 
significant increases in the frequency of cells with aberrations or polyploid cell frequency at any 
concentration, either in the absence or presence of S9-mix. 
In conclusion, vetiveryl acetate did not induce chromosomal aberrations in cultured human peripheral 
blood lymphocytes when tested for 4 + 20 hours up to 45 μg/ml or 100 μg/ml, in the absence or in the 
presence of rat liver metabolic activation (S9-mix), respectively. In the same test system, vetiveryl 
acetate did not induce chromosomal aberrations when tested for 24 hours of continuous exposure up to 
100 μg/ml in the absence of S9-mix. 
CONCLUSION 
Industry submitted additional genotoxicity data for vetiveryl acetate [FL-no: 09.821]. 
The overall conclusion for the in vitro genotoxicity data indicate that the FGE.19 subgroup 2.6 
substance, vetiveryl acetate, does not give rise to a safety concern with respect to genotoxicity, and 
accordingly, vetiveryl acetate [FL-no: 09.821] and the corresponding alcohol moiety, vetiverol [FL-
no: 02.214] can be evaluated using the Procedure. 
For the remaining five substances [FL-no: 07.033, 07.094, 07.112, 07.140 and 07.219] from subgroup 
2.6, there is still a genotoxicity concern and additional data are required. 
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SUMMARY OF SPECIFICATION FOR SUBSTANCES IN FGE.212REV2 (JECFA, 1998; JECFA, 2002; JECFA, 2009B) 
Table 2:  Specification Summary of the Substances in the Flavouring Group Evaluation 212Rev2 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formul
a 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
02.062 
381 
Carveol 
OH
 
2247 
2027 
99-48-9 
Liquid 
C10H16O    
152.24 
 
Freely soluble 
226-227 
 
IR 
96 % 
1.493-1.497 
0.947-0.953 
02.083 
434 
p-Menth-1-en-3-ol 
OH
 
3179 
10248 
491-04-3 
Liquid 
C10H18O   
154.25 
 
 
232 
 
NMR 
97 % 
1.4762 (25C) 
0.930-0.936 
02.101 
1404 
Pin-2-en-4-ol   6) 
HO
 
3594 
10304 
473-67-6 
Solid 
C10H16O 
152.24 
Very slightly 
soluble 
Soluble 
n.a. 
63-67 
NMR 
95 % 
n.a. 
n.a. 
02.214 
1866 
Vetiverol 
HO
 
4217 
10321 
89-88-3 
Solid 
C15H24O 
220.35 
Practically 
insoluble or 
insoluble 
Freely soluble 
n.a. 
69 
NMR 
95 % 
n.a. 
n.a. 
07.033 
1115 
Isojasmone   6) 
O
+
O
 
3552 
167 
11050-62-7 
Liquid 
C11H18O 
166.26 
 
 
144 (13 hPa) 
 
NMR 
95 % 
1.472-1.477 
0.917-0.924 
07.035 
1111 
Tetramethyl ethylcyclohexenone 
(mixture of isomers) 
OO
29 % 68 %
+
 
3061 
168 
17369-60-7 
Liquid 
C12H20O 
180.29 
Slightly soluble 
Miscible 
113-115 
 
NMR 
97 % 
1.485-1.490 
0.927-0.934 
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Table 2:  Specification Summary of the Substances in the Flavouring Group Evaluation 212Rev2 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formul
a 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
07.094 
1114 
3-Methyl-2-(pent-2(cis)-
enyl)cyclopent-2-en-1-one 
O
 
3196 
11786 
488-10-8 
Liquid 
C11H16O 
164.25 
 
 
248 
 
NMR 
98 % 
1.495-1.501 
0.942-0.948 
07.098 
1107 
3-Methylcyclohex-2-en-1-one 
O
 
3360 
11134 
1193-18-6 
Liquid 
C7H10O 
110.16 
Miscible 
Miscible 
199-200 
 
NMR 
98 % 
1.490-1.498 
0.967-0.972 
07.112 
1105 
3-Methyl-2-cyclopenten-1-one 
O
 
3435 
11137 
2758-18-1 
Liquid 
C6H8O 
96.12 
 
 
74 (20 hPa) 
 
NMR 
98 % 
1.485-1.491 
0.968-0.975 
07.126 
1112 
3,5,5-Trimethylcyclohex-2-en-1-one 
O
 
3553 
11918 
78-59-1 
Liquid 
C9H14O 
138.21 
Slightly soluble 
Miscible 
213-215 
 
NMR 
97 % 
1.474-1.481 
0.919-0.927 
07.129 
1113 
3-Methyl-5-propylcyclohex-2-en-1-one 
O
 
3577 
 
3720-16-9 
Liquid 
C10H16O 
152.23 
Insoluble 
Miscible 
242-244 
 
NMR 
95 % 
1.481-1.486 
0.924-0.928 
07.140 
1406 
3-Methyl-2-pentylcyclopent-2-en-1-one 
O
 
3763 
 
1128-08-1 
Liquid 
C11H18O 
166.26 
Very slightly 
soluble 
Soluble 
79 (0.2 hPa) 
 
NMR 
99 % 
1.676-1.682 
0.911-0.917 
07.146 
380.1 
d-Carvone 
O
 
 
 
2244-16-8 
 
 
 
 
 
 
 
 
 
 
 
07.147 
380.2 
l-Carvone 
O
 
 
 
6485-40-1 
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Table 2:  Specification Summary of the Substances in the Flavouring Group Evaluation 212Rev2 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formul
a 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
07.172 
1110 
4-Isopropylcyclohex-2-en-1-one 
O
 
3939 
11127 
500-02-7 
Liquid 
C9H14O 
138.21 
Insoluble 
Miscible 
198 
 
NMR 
97 % 
1.481-1.490 
0.930-0.950 
07.175 
435 
p-Menth-1-en-3-one 
(+/- piperitone) 
O
 
2910 
2052 
89-81-6 
Liquid 
C10H16O 
152.24 
Insoluble 
 
233-235 
 
IR 
94 % 
1.483-1.487 
0.929-0.934 
07.196 
1870 
Pin-2-en-4-one   6) 
O  
4216 
11186 
80-57-9 
Liquid 
C10H14O 
150.22 
Insoluble 
Freely soluble 
90 (16 hPa) 
 
NMR MS 
95 % 
1.492-1.498 
0.975-0.981 
07.202 
 
2,6,6-Trimethylcyclohex-2-en-1-one 
O
 
 
 
20013-73-4 
Liquid 
C9H14O 
138.21 
Slightly soluble 
Freely soluble 
63 (16 hPa) 
 
MS 
95 % 
1.470-1.476 
0.924-0.930 
07.219 
 
trans-3-Methyl-2-(2-pentenyl)-2-
cyclopenten-1-one 
O  
3196 
11786 
6261-18-3 
Liquid 
C11H16O 
164.25 
Soluble 
Soluble 
248 
 
MS 
98 % 
1.495-1.501 
0.942-0.948 
07.255 
1856 
l-Piperitone 
O
R
 
4200 
 
4573-50-6 
Liquid 
C10H16O 
152.24 
Slightly soluble 
Freely soluble 
246 
 
MS 
99 % 
1.482-1.488 
0.929-0.935 
09.143 
383 
Carvyl propionate 
O
O
 
2251 
424 
97-45-0 
Liquid 
C13H20O2   
208.30 
Insoluble 
 
239 
 
IR 
98 % 
1.469-1.479 
0.942-0.962 
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Table 2:  Specification Summary of the Substances in the Flavouring Group Evaluation 212Rev2 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formul
a 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
09.215 
382 
Carvyl acetate 
OO
 
2250 
2063 
97-42-7 
Liquid 
C12H18O2  
194.27 
Slightly soluble 
 
229 
 
IR 
98 % 
1.473-1.479 
0.964-0.970 
09.821 
1867 
Vetiveryl acetate 
O
O  
4218 
11887 
117-98-6 
Solid 
C17H26O2 
262.39 
 
Freely soluble 
406 
73 
 
95 % 
n.a. 
n.a. 
09.870 
 
Carvyl-3-methylbutyrate 
O
O
 
 
 
94386-39-7 
Liquid 
C15H24O2 
236.37 
Practically 
insoluble or 
insoluble 
Freely soluble 
343 
 
MS 
95 % 
1.462-1.468 
0.932-0.938 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 % ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (JECFA, 1999; JECFA, 2003; JECFA, 2009A) 
Table 3:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) 
( g/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[ 4) or 5)] 
Outcome on the material of 
commerce [6), 7), or 8)] 
02.062 
381 
Carveol 
OH
 
9.5 
140 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.212, genotoxic 
concern could be ruled out. Evaluated 
by JECFA before 2000. No further 
EFSA consideration required 
02.083 
434 
p-Menth-1-en-3-ol 
OH
 
0.012 
0.02 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could be ruled out. 
Evaluated by JECFA before 2000. No 
further EFSA consideration required 
02.101 
1404 
Pin-2-en-4-ol 
HO
 
0.012 
0.2 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxicity concern could be ruled 
out. Evaluated through the Procedure 
in FGE.87Rev1. No safety concern at 
the estimated level of intake based on 
the MSDI approach. 
09.143 
383 
Carvyl propionate O
O
 
ND 
0.04 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.212, genotoxic 
concern could be ruled out. Evaluated 
by JECFA before 2000. No further 
EFSA consideration required 
09.215 
382 
Carvyl acetate 
OO
 
4.0 
36 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.212, genotoxic 
concern could be ruled out. Evaluated 
by JECFA before 2000. No further 
EFSA consideration required 
09.870 
 
Carvyl-3-methylbutyrate 
O
O
 
0.0012 
 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.212, genotoxic 
concern could be ruled out. Evaluated 
through the Procedure in 
FGE.09Rev2. No safety concern at 
the estimated level of intake based on 
the MSDI approach. 
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Table 3:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) 
( g/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[ 4) or 5)] 
Outcome on the material of 
commerce [6), 7), or 8)] 
07.033 
1115 
Isojasmone 
O
+
O
 
0.37 
0.01 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could not be ruled 
out. Additional genotoxicity data 
required for the representative [FL-
no: 07.112] 
07.035 
1111 
Tetramethyl 
ethylcyclohexenone 
(mixture of isomers) 
OO
29 % 68 %
+
 
7.8 
0.2 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could be ruled out. 
Evaluated through the Procedure in 
FGE.51Rev1. No safety concern at 
the estimated level of intake based on 
the MSDI approach. 
07.094 
1114 
3-Methyl-2-(pent-2(cis)-
enyl)cyclopent-2-en-1-
one 
O
 
13 
7.2 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could not be ruled 
out. Additional genotoxicity data 
required for the representative [FL-
no: 07.112] 
07.098 
1107 
3-Methylcyclohex-2-en-1-
one 
O
 
0.012 
0.1 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could be ruled out. 
Evaluated through the Procedure in 
FGE.51Rev1. No safety concern at 
the estimated level of intake based on 
the MSDI approach. 
07.112 
1105 
3-Methyl-2-cyclopenten-
1-one 
O
 
0.06 
ND 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could not be ruled 
out. Additional genotoxicity data 
required for the representative [FL-
no: 07.112] 
07.126 
1112 
3,5,5-Trimethylcyclohex-
2-en-1-one 
O
 
4.6 
0.1 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could be ruled out. 
Evaluated through the Procedure in 
FGE.51Rev1. No safety concern at 
Flavouring Group Evaluation 212, Revision 2  
 
EFSA Journal 2014;12(2):3584 23 
Table 3:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) 
( g/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[ 4) or 5)] 
Outcome on the material of 
commerce [6), 7), or 8)] 
the estimated level of intake based on 
the MSDI approach. 
07.129 
1113 
3-Methyl-5-
propylcyclohex-2-en-1-
one 
O
 
0.097 
4.1 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could be ruled out. 
Evaluated through the Procedure in 
FGE.51Rev1. No safety concern at 
the estimated level of intake based on 
the MSDI approach. 
07.140 
1406 
3-Methyl-2-
pentylcyclopent-2-en-1-
one 
O
 
0.34 
0.2 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could not be ruled 
out. Additional genotoxicity data 
required for the representative [FL-
no: 07.112] 
07.172 
1110 
4-Isopropylcyclohex-2-
en-1-one 
O
 
0.0012 
0.001 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could be ruled out. 
Evaluated through the Procedure in 
FGE.51Rev1. No safety concern at 
the estimated level of intake based on 
the MSDI approach. 
07.175 
435 
p-Menth-1-en-3-one 
(+/- piperitone) 
O
 
44 
10 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxicity concern could be ruled 
out. Evaluated by JECFA before 
2000. No further EFSA consideration 
required. 
07.196 
1870 
Pin-2-en-4-one 
O  
15 
 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxicity concern could be ruled 
out. Evaluated through the Procedure 
in FGE.47Rev1. No safety concern at 
the estimated level of intake based on 
the MSDI approach. 
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Table 3:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) 
( g/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[ 4) or 5)] 
Outcome on the material of 
commerce [6), 7), or 8)] 
07.202 
 
2,6,6-Trimethylcyclohex-
2-en-1-one 
O
 
0.12 
 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could be ruled out. 
Evaluated through the Procedure in 
FGE.09Rev4. No safety concern at 
the estimated level of intake based on 
the MSDI approach. 
07.255 
1856 
l-Piperitone 
O
R
 
12 
 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev1, 
genotoxic concern could be ruled out. 
Evaluated through the Procedure in 
FGE.09Rev4. No safety concern at 
the estimated level of intake based on 
the MSDI approach. 
07.146 
380.1 
d-Carvone 
O
 
2390 
9900 
Class II 
A3: Intake above threshold, A4: 
Not endogenous, A5: Adequate 
NOAEL exists 
4) Evaluated in FGE.212, genotoxicity 
concern could be ruled out. Evaluated 
by JECFA before 2000. No further 
EFSA consideration required. 
07.147 
380.2 
l-Carvone 
O
 
2390 
9900 
Class II 
A3: Intake above threshold, A4: 
Not endogenous, A5: Adequate 
NOAEL exists 
4) Evaluated in FGE.212, genotoxic 
concern could be ruled out. Evaluated 
by JECFA before 2000. No further 
EFSA consideration required. 
02.214 
1866 
Vetiverol 
HO
 
0.011 
 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212Rev2, 
genotoxic concern can  be ruled out. 
Can be evaluated through the 
Procedure in FGE.47Rev2. 
09.821 
1867 
Vetiveryl acetate 
O
O  
0.011 
 
Class II 
A3: Intake below threshold 
4) Evaluated in FGE.212 Rev2, 
genotoxic concern can  be ruled out.  
Can be evaluated using the Procedure 
in FGE.47Rev2. 
07.219 
 
trans-3-Methyl-2-(2-
pentenyl)-2-cyclopenten-
1-one 
O  
4.7 
 
 
No evaluation 
Not evaluated by 
the JECFA 
Evaluated in FGE.212Rev2, 
genotoxic concern could not be ruled 
out. Additional genotoxicity data 
required for the representative [FL-
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Table 3:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) 
( g/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[ 4) or 5)] 
Outcome on the material of 
commerce [6), 7), or 8)] 
no: 07.112] 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
 
 
Flavouring Group Evaluation 212, Revision 2  
 
EFSA Journal 2014;12(2):3584 26 
QSAR PREDICTIONS ON MUTAGENICITY IN FIVE MODELS FOR 16 KETONES FROM SUBGROUP 2.6 
Table 4:  QSAR Predictions on Mutagenicity in Five Models for 16 Ketones from Subgroup 2.6 
FL-no 
JECFA-no 
EU Register name Structural formula ISS Local Model 
Ames Test 
TA100 
MultiCASE 
Ames test 
 
MultiCASE 
Mouse 
lymphoma test 
MultiCASE 
Chromosomal 
aberration test in 
CHO 
MultiCASE 
Chromosomal 
aberration test in 
CHL 
Not in 
Register 
2,6-Dimethyl-9-(1-
methylethylidene)-
bicyclo[5.3.0]dec-2-en-4-one 
O
 
OD NEG NEG NEG NEG 
07.033 
1115 
Isojasmone 
O
 
OD NEG NEG NEG NEG 
07.094 
1114 
3-Methyl-2-(pent-2(cis)-
enyl)cyclopent-2-en-1-one 
O
 
OD NEG OD NEG NEG 
07.098 
1107 
3-Methylcyclohex-2-en-1-one 
O
 
OD NEG POS NEG EQU 
07.112 
1105 
3-Methyl-2-cyclopenten-1-one 
O
 
OD NEG POS NEG EQU 
07.126 
1112 
3,5,5-Trimethylcyclohex-2-en-1-
one 
O
 
OD NEG POS NEG EQU 
07.129 
1113 
3-Methyl-5-propylcyclohex-2-en-1-
one 
O
 
OD NEG POS NEG EQU 
07.140 
1406 
3-Methyl-2-pentylcyclopent-2-en-
1-one 
O
 
OD NEG OD NEG NEG 
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Table 4:  QSAR Predictions on Mutagenicity in Five Models for 16 Ketones from Subgroup 2.6 
FL-no 
JECFA-no 
EU Register name Structural formula ISS Local Model 
Ames Test 
TA100 
MultiCASE 
Ames test 
 
MultiCASE 
Mouse 
lymphoma test 
MultiCASE 
Chromosomal 
aberration test in 
CHO 
MultiCASE 
Chromosomal 
aberration test in 
CHL 
07.146 
380.1 
d-Carvone 
O
 
OD NEG NEG NEG NEG 
07.147 
380.2 
l-Carvone 
O
 
OD NEG NEG NEG NEG 
07.172 
1110 
4-Isopropylcyclohex-2-en-1-one O
 
OD NEG NEG NEG EQU 
07.202 
 
2,6,6-Trimethylcyclohex-2-en-1-
one 
O
 
OD NEG OD NEG NEG 
07.035 
1111 
Tetramethyl ethylcyclohexenone 
(mixture of isomers) 
OO
29 % 68 %
+
 
OD NEG NEG NEG NEG 
07.255 
 
l-Piperitone 
O
 
OD NEG OD NEG EQU 
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Table 4:  QSAR Predictions on Mutagenicity in Five Models for 16 Ketones from Subgroup 2.6 
FL-no 
JECFA-no 
EU Register name Structural formula ISS Local Model 
Ames Test 
TA100 
MultiCASE 
Ames test 
 
MultiCASE 
Mouse 
lymphoma test 
MultiCASE 
Chromosomal 
aberration test in 
CHO 
MultiCASE 
Chromosomal 
aberration test in 
CHL 
07.196 
- 
Pin-2-en-4-one 
O  
OD NEG POS NEG POS 
07.175 p-Menth-1-en-3-one 
(+/- piperitone) 
O
 
OD NEG POS NEG  OD 
Column 3: Structure group 2.6: , -unsaturated ketones. 
Column 4: Local model on aldehydes and ketones, Ames TA100. (NEG: Negative; POS: Positive; OD*: out of domain). 
Column 5: MultiCase Ames test (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
Column 6: MultiCase Mouse Lymphona test (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
Column 7: MultiCase Chromosomal aberration in CHO (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
Column 8: MultiCase Chromosomal aberration in CHL (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
*  OD, out of applicability domain: not matching the range of conditions where a reliable prediction can be obtained in this model. These conditions may be physicochemical, structural, 
biological etc. 
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CARCINOGENICITY STUDIES CONSIDERED BY THE PANEL IN FGE.212 
Table 5:  Carcinogenicity Studies 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration Results Reference Comments* 
3,5,5-Trimethylcyclohex-
2-en-1-one [07.126] 
Rats; Male, 
Female 
50/sex/group 
Gavage in 
corn oil 
0 (controls), 250 or 500 
mg/kg bw/day, five times 
per week 
103 weeks Males: Increased  incidences of renal tubular cell 
adenomas and adenocarcinomas and of 
carcinomas of the preputial gland   
Females: No carcinogenic effect 
(NTP, 
1986) 
Valid 
Mice; Male, 
Female 
50/sex/group 
Gavage in 
corn oil 
0 (controls), 250 or 500 
mg/kg bw/day, five times 
per week  
103 weeks Males: Increased  incidences of hepatocellular 
adenomas and carcinomas, mesenchymal tumors 
in the integumentary system, and malignant 
lymphomas 
Females: No carcinogenic effect 
(NTP, 
1986) 
Valid 
d-Carvone [07.146] Mice; Male, 
Female 
50/sex/group 
Gavage 0,  375 or 750 mg/kg 
bw/day,  five times per 
week 
103 weeks Males and females: No increases in tumour 
incidences  
(NTP, 
1990) 
Valid 
*  Validity of genotoxicity studies: 
 Valid. 
 Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
 Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system). 
 Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). 
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GENOTOXICITY DATA (IN VITRO) CONSIDERED BY THE PANEL IN FGE.212 AND FGE.212REV1 
Table 6:  Summary of Genotoxicity data (in vitro) 
Chemical Name  
[FL-no]  
Test System Test Object  Concentration Reported 
Result  
Reference  Comments e 
Tetramethyl 
ethylcyclohexenone (mixture 
of isomers) [07.035] 
Reverse mutation S. typhimurium TA98, TA100, 
TA1535, TA1537, TA1538 
5 concentrations up to 
cytotoxicity or max. 
3600 µg/plate 
Negativea (Wild et al., 1983) Limited validity (no TA102 or 
E. Coli); possibly slightly low  
maximal concentration tested. 
3,5,5-Trimethylcyclohex-2-
en-1-one [07.126] 
Reverse mutation S. typhimurium TA97, TA98, 
TA100, TA1535, TA1537 
33 – 10000 µg/plate Negativea (Mortelmans et al., 
1986) 
Valid 
Mutation S. typhimurium TA98, TA100, 
TA1535, TA1537 
33 – 10000 µg/plate Negativea (NTP, 1986) NTP study carried out 
according to standard US-EPA 
Guideline; result is considered 
as valid. 
Mutation L5178YTk+/– mouse lymphoma 
cells 
67 – 810 µg/ml Negativec (McKee et al., 
1987) 
Validity cannot be evaluated 
(tested with S9; abstract only 
with very limitred 
information). 
Mutation L5178YTk+/– mouse lymphoma 
cells 
130 – 1300 µg/ml Negativeb (McKee et al., 
1987) 
Validity cannot be evaluted 
(tested without S9; abstract 
only with very limitred 
information). 
Mutation L5178YTk+/– mouse lymphoma 
cells 
0.089 – 0.89 µl/ml Negativec (O’Donoghue et 
al., 1988) 
Valid according to current 
guidelines 
Mutation L5178YTk+/– mouse lymphoma 
cells 
0.13 – 1.3 µl/ml Negativeb  (O’Donoghue et 
al., 1988) 
Valid according to current 
guidelines 
Mutation L5178YTk+/– mouse lymphoma 
cells 
1200 µg/ml Positiveb 
 
(NTP, 1986) NTP study carried out 
according to standard US-EPA 
Guideline. Not tested with S9. 
Result is considered as valid. 
Mutation L5178YTk+/– mouse lymphoma 
cells 
Not reported (however, 
up to cytotoxic 
concentrations) for 3 
hours exposure.  
Negativea (Honma et al., 
1999a) 
Limited validity since data 
were presented in a 
summarised table format only 
(as a result of an international 
Flavouring Group Evaluation 212, Revision 2  
 
EFSA Journal 2014;12(2):3584 31 
Table 6:  Summary of Genotoxicity data (in vitro) 
Chemical Name  
[FL-no]  
Test System Test Object  Concentration Reported 
Result  
Reference  Comments e 
collaborative study). 
Mutation L5178YTk+/– mouse lymphoma 
cells 
Up to 1500 µg/ml Positiveb 
 
(Honma et al., 
1999b) 
Limited validity since 
mutation frequencies were not 
reported in table format. 
Tested only in the absence of 
S9. Isophorone was mutagenic 
after 24-hour treatments in the 
absence of S9. Although only 
graphs are plotted, it seems 
that increases in MF that 
exceeded the GEF occurred at 
around 1250‐1500 μg/ml 
where toxicity (by relative 
survival) reached 70‐90 %. 
Chromosomal 
aberration 
Chinese hamster ovary cells 5 – 1600 µg/ml Negativea (Gulati et al., 1989) Limited validity (not clear if 
gaps were included in the 
scores). 
Chromosomal 
aberration 
Chinese hamster ovary cells 250 – 1600 µg/ml Negativea (NTP, 1986) NTP study carried out 
according to standard US-EPA 
Guideline; result is considered 
as valid. 
Chromosomal 
aberration  
Chinese hamster lung fibroblasts  0 - 1250b µg/ml  
0 – 1500c µg/ml 
Positivea (Matsuoka et al., 
1996) 
Valid. 
Chromosomal 
aberration  
Chinese hamster lung fibroblasts  250 – 1000 mg/ml Negativea (Matsuoka et al., 
1996) 
Valid. Exposed to isophorone 
without metabolic activation 
for 24 or 48 hours, cytotoxic at 
highest concentrations. 
Sister chromatid 
exchange 
Chinese hamster ovary cells 5 – 1600 mg/ml Positiveb,d  (Gulati et al., 1989) Valid (pos – S9; neg + S9). 
Sister chromatid 
exchange 
Chinese hamster ovary cells 160 – 1000 mg/ml Negativea (NTP, 1986) NTP study carried out 
according to Standard US-
EPA Guideline; result is 
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Table 6:  Summary of Genotoxicity data (in vitro) 
Chemical Name  
[FL-no]  
Test System Test Object  Concentration Reported 
Result  
Reference  Comments e 
considered as valid. 
Unscheduled DNA 
synthesis 
Rat hepatocytes 0.005 – 0.4 µl/ml Negative (O’Donoghue et 
al., 1988) 
Valid according to current 
guidelines 
Unscheduled DNA 
synthesis 
Rat hepatocytes 5 - 200 µl/ml Negativea (McKee et al., 
1987) 
Validity cannot be evaluated 
(abstract only with very 
limited information) 
Carvone (isomer not 
specified) 
Gene mutation S. typhimurium TA1535, 
TA1537, TA98, TA100 
3 µmol/plate Negative (Florin et al., 1980) Insufficient validity (spot test, 
not according to OECD 
Guideline, methods and results 
insufficiently reported). 
Isomer (d or l) not reported. 
Rec assay B. subtilis H17 (rec+) and M45 
(rec-) 
0.6 ml/disc Negative (Matsui et al., 
1989) 
The test system used is 
considered inappropriate,  
d-Carvone [07.0146] Gene mutation  S. typhimurium TA1535, TA98, 
TA100, TA1537 
333 µg/plate Negativea (NTP, 1990) Valid 
Gene mutation (pre-
incubation) 
S. typhimurium TA1535, TA98, 
TA100, TA1537 
560 µg/plate Negative (Mortelmans et al., 
1986) 
Valid 
Sister chromatid 
exchange 
Chinese hamster ovary cells 502 µg/ml Positivea (NTP, 1990) Valid 
Chromosomal 
aberration 
Chinese hamster ovary cells 400 µg/ml Positivea (NTP, 1990) Valid 
a: With and without metabolic activation. 
b: Without metabolic activation. 
c: With metabolic activation. 
d: Cytotoxic at next highest dose tested (1600 mg/ml). 
e: Validity of genotoxicity studies: 
 Valid. 
 Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
 Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate  test system). 
 Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). 
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GENOTOXICITY DATA (IN VIVO) CONSIDERED BY THE PANEL IN FGE.212 AND IN FGE.212REV1 
Table 7:  Summary of Genotoxicity data (in vivo) 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments a 
Tetramethyl 
ethylcyclohexenone (mixture 
of isomers [07.035] 
Sex-linked 
recessive lethal 
mutation 
D. melanogaster Feed  10 mM Negative (Wild et al., 
1983) 
Limited validity (low nr of chromosomes, 
limited reporting). 
Micronucleus 
formation 
Mouse bone 
marrow 
i.p. 180, 307 and 450 
mg/kg bw 
Negative (Wild et al., 
1983) 
Limited validity. Only analysis at one 
time point; no PCE/NCE ratio reported. 
3,5,5-Trimethylcyclohex-2-
en-1-one [07.126] 
Sex-linked 
recessive lethal 
mutation 
D. melanogaster  2000f  and 12500g  ppm Negative (Foureman et 
al., 1994) 
Valid, however, only limited relevance. 
Micronucleus 
formation 
CD-1 mice i.p. 540 mg/kg bw (MTD) Negative (McKee et al., 
1987) 
Validity cannot be evaluated. Abstract 
only; very limited information no data  on 
PCE/NCE ratio. 
CD-1 mice i.p. 0.54 ml/kg bw Negative (O’Donoghue 
et al., 1988) 
Limited validity. Only one dose level 
tested, this dose level corresponded to the 
LD20; sample schedule inadequate 
Chromosomal 
aberration 
B6C3F1 mice i.p. 125, 250 and 500 
mg/kg bw 
Negative NTP-Website Valid. Submitted by Industry in 2009. 
The standard protocol for in vivo CA is 
not given on the NTP website. However, 
based on Shelby and Witt (1995), animals 
should have been sampled at 17 hours 
and, if negative, also at 36 hours. The data 
on the NTP website are only for bone 
marrow sampled at 36 hours. It is 
therefore possible that a 17 hours sample 
was also taken, and found to be negative, 
but the data not posted. Fifty cells per 
animal were scored for CA and no 
increases in CA were seen. No measures 
of toxicity were recorded, but i.p. dosing 
should have guaranteed systemic 
exposure. 
DNA binding F344 rats Gavage 500 mg unlabelled 
isophorone / kg bw 
Negative Thier et al., 
1990 
Limited validity. Submitted by Industry in 
2009. No positive controls and no 
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spiked with C14 
isophorone  (0.4 
mCi/rat) 
untreated controls used. Liver and kidney 
were analysed. 
DNA binding B6C3F1 mice Gavage 500 mg unlabelled 
isophorone / kg bw 
spiked with C14 
isophorone (0.08 
mCi/mouse) 
Negative Thier et al., 
1990 
Limited validity. Submitted by Industry in 
2009. No positive controls and no 
untreated controls used. Liver and kidney 
were analysed. 
DNA binding F344 rats (10 
males) 
Gavage 500 mg/kg bw 14C-
isophorone (0.1 
mCi/rat) 
Negative Morishita et 
al., 1997 
Valid. Preputial glands and kidneys were 
analysed. 
DNA adducts (32P-
Postlabelling) 
F344 rats (7 
males and 7 
females per dose 
group) 
Gavage 0, 250 and 500 
mg/kg/day  for 5 days. 
Negative Morishita et 
al., 1997 
Valid. Preputial glands were analysed. 
a: Validity of genotoxicity studies: 
 Valid. 
 Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
 Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system). 
 Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). 
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GENOTOXICITY DATA (IN VITRO) CONSIDERED BY THE PANEL IN FGE.212REV2 
Table 8:  Summary of Additionally Genotoxicity Data on [FL-no: 09.821] of Subgroup 2.6 
Chemical Name 
[FL-no:] 
Test System in 
vitro  
Test Object  Concentrations of 
Substance and Test 
Conditions  
Result  Reference  Comments  
Vetiveryl acetate 
[09.821] 
Reverse Mutation S. typhimurium 
TA97, TA98, TA100, 
TA102, and TA1535 
20, 63.2, 200, 632 and 
2000 μg/plate [6,7] 
 
20, 63.2, 200, 632 and 
2000 μg/plate [6,8] 
Negative 
 
 
Negative 
(Gocke, 2000) 1 % alpha-tocopherol was present in the solution of 
vetiveryl acetate as a stabiliser. Some precipitation 
(milky appearance) was seen at the higher 
concentrations and there was some evidence of toxicity 
in the pre-incubation experiments. Study design 
complies with current recommendations (OECD, 
Guideline 471). 
S. typhimurium TA100, 
TA97a, TA98, TA1535, 
and TA102 
5 - 5000 μg/plate [6,7] 
 
5 - 5000 μg/plate [6,8] 
Negative 
 
Negative 
(Scheerbaum, 
2001) 
Limited toxicity was noted at 500, 1600 or 5000 
μg/plate. No precipitation was seen. Study design 
complies with current recommendations (OECD, 
Guideline 471). 
S. typhimurium TA98, 
TA100, TA102, 
TA1535 and TA1537 
 
S. typhimurium TA98, 
TA1535 and TA1537 
 
 
S. typhimurium TA100, 
TA102 
 
33, 100, 333, 1000, 
2500 and 5000 μg/plate 
[6,7] 
 
33, 100, 333, 
1000, 2500 and 5000 
μg/plate [6,8] 
 
10 [9, 8] 
33, 100, 333, 
1000, 2500 and 5000 
μg/plate [6,8] 
 
Negative 
 
 
 
Negative 
 
 
 
Negative 
(Poth, 2003) Stabilized material (18 months). Precipitation occurred 
at the highest concentration. In the first experiment, 
cytotoxicity was noted in the presence of S9-mix at 
1000 μg/plate and above (TA100 and TA102) or at 
5000 μg/plate (TA1537). In the second experiment, 
cytotoxicity was noted in the presence of S9-mix, at 
1000 μg/plate and above (TA1537 and TA100) and at 
2500 μg/plate and above (TA1535 and TA102). Study 
design complies with current recommendations 
(OECD, Guideline 471). 
S. typhimurium TA98, 
TA100, TA102, 
TA1535 and TA1537 
33, 100, 333, 1000, 
2500 and 5000 
μg/plate [6,7] 
 
33, 100, 333, 1000, 
2500 and 5000 
μg/plate [6,8] 
Negative 
 
 
 
Negative 
(Sokolowski, 
2003a) 
Stabilized material (24 months). No precipitation was 
observed up to the highest concentration. Cytotoxicity 
was noted in the presence of S9-mix, at 1000 μg/plate 
and above. Study design complies with current 
recommendations (OECD, Guideline 471). 
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Table 8:  Summary of Additionally Genotoxicity Data on [FL-no: 09.821] of Subgroup 2.6 
Chemical Name 
[FL-no:] 
Test System in 
vitro  
Test Object  Concentrations of 
Substance and Test 
Conditions  
Result  Reference  Comments  
S. typhimurium TA98, 
TA100, TA102, 
TA1535 and TA1537 
33, 100, 333, 1000, 
2500 and 5000 μg/plate 
[6,7] 
 
33, 100, 333, 1000, 
2500 and 5000 μg/plate 
[6,8] 
Negative 
 
 
 
Negative 
(Sokolowski, 
2003b) 
Stabilised material 112 extra (24 months). No 
precipitation was observed up to the highest 
concentration. Cytotoxicity was noted in the presence 
of S9-mix, at 1000 μg/plate and above. Study design 
complies with current recommendations (OECD, 
Guideline 471). 
Chromosomal 
aberrations 
Human Lymphocytes 10 - 60 μg/ml [1,4]; 
40 - 140 μg/ml [2,4]; 
20 - 140 μg/ml [3,4]; 
10 - 120 μg/ml [1,5] 
Negative (Morris, 2011) The dose selection was based on a preliminary toxicity 
test performed in CHO cells, in a previous 
chromosome aberration study (Morris and Durward, 
2010). Hemolysis was observed at 20 μg/ml and 80 
μg/ml in the absence and presence of S9-mix, 
respectively. No precipitation was observed.  Study 
design complies with current recommendations 
(OECD, Guideline 473). 
Chinese Hamster Ovary 
Cells 
2.5 - 40 μg/ml [1,4]; 
10 - 80 μg/ml [2,4]; 
10 - 70 μg/ml [3,4]; 
5 - 35 μg/ml [1,5] 
Negative (Morris and 
Durward, 2010) 
Small increases in chromosomal aberrations and 
polyploidy were not dose-dependent and not consistent, 
and therefore they were considered of no biological 
significance. A marked toxicity was observed at 
concentrations higher than 82 μg/ml in the absence of 
S9-mix and higher than 164 μg/ml in the presence of 
S9-mix (4+20 hours). A marked toxicity was observed 
at concentrations higher than 41 μg/ml in the 24 hour 
continuous exposure group.  
In the first experiment, the maximum concentrations 
selected for metaphase analysis were 30 μg/ml and 60 
μg/ml in the absence and presence of S9-mix 
respectively. In the second experiment, the maximum 
concentrations selected for analysis were 20 μg/ml and 
50 μg/ml in the absence and presence of S9-mix 
respectively. Precipitation was seen at 30 μg/ml and 
above or 50 μg/ml and above, in the absence or 
presence of S9-mix, respectively. Study design 
complies with current recommendations (OECD, 
Guideline 473). 
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[1] Without S9-mix metabolic activation. 
[2] With S9-mix metabolic activation (2%). 
[3] With S9-mix metabolic activation (1%). 
[4] 4-hour incubation with 20-hour recovery period. 
[5] 24-hour incubation with no recovery period. 
[6] With and without S9-mix metabolic activation. 
[7] Standard plate incorporation method. 
[8] Modified pre-incubation method. 
[9]With S9-mix metabolic activation. 
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ABBREVIATIONS 
bw  Body Weight 
CA  Chromosomal Aberrations 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids  
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
CP  Cyclophosphamide 
DMSO  Dimethylsulfoxyd 
DNA  Deoxyribonucleic acid 
dpm  Disintegrations Per Minute 
EC  European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GEF  Global Evaluation Factor 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
i.p.  intraperitoneal 
IR   Infrared spectroscopy 
JECFA  Joint FAO/WHO Expert Committee on Food Additives 
MF  Mutation Frequency 
MLA   Mouse Lymphoma Assay  
MLTK  Mouse Lymphoma Thymidine Kinase (gene mutation assay) 
MMC  Mitomycin C 
MS  Mass spectrometry 
NCE  Normochromatic Erythrocytes 
No  Number 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PCE  Polychromatic Erythrocytes 
QSAR  Quantitative Structure-Activity Relationship 
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SCE  Sister Chromatid Exchange 
SLRL  Sex Linked Recessive Lethal Mutations test 
UDS  Unscheduled DNA Synthesis 
WHO  World Health Organisation  
